A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin

• Status: Completed
• Trial end date: 2016-05-31
• Target enrollment: 0
• Participant gender: All

Summary

This is a single cohort observational safety study. All patients will be treated and monitored according to the local clinical practice. No additional procedures/patient visits in comparison with the usual clinical practice are planned for the study. Data will be collected from centre's medical records for up to 5 years or death.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Trastuzumab

Criteria

Inclusion Criteria:

• All patients who are considered candidates to receive Herceptin for this indication

Exclusion Criteria:

• Patients for whom Herceptin is contraindicated